The overlapping development programs for first-generation larotrectinib and second-generation LOXO-195 signal narrowing drug development timelines in the era of precision oncology.
In development for several years, PORTIN is now being deployed as a single point of reference for all genotype and phenotype data at Bayer's research sites.
Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.
The deal with ERS Genomics, a commercialization vehicle for Emmanuelle Charpentier's patents, gives the Bayer LifeScience Center access to CRISPR/Cas9 genome editing.
